108 related articles for article (PubMed ID: 38874255)
1. Molecular Subgrouping Based on Immunohistochemistry in Medulloblastoma: a Single-Center Experience.
Babaoglu B; Hanalioglu S; Varan A; Oguz KK; Bilginer B; Dolgun A; Soylemezoglu F
Turk Neurosurg; 2024 Jan; ():. PubMed ID: 38874255
[TBL] [Abstract][Full Text] [Related]
2. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
3. Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience.
Badiger S; Gudipati A; Uppin M; Konatam ML; Yeramneni VK; Bhattacharjee S; Saradhi MV; Patnaik S; Irukulla M
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S592-S602. PubMed ID: 38384024
[TBL] [Abstract][Full Text] [Related]
4. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma.
Chinnam D; Saraswati A; Jogunoori S; Verma A; Kiran T; Salunke P; Gupta N; Kumar N; Madan R; Radotra BD; Gupta K
Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):561-568. PubMed ID: 37471625
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
[TBL] [Abstract][Full Text] [Related]
7. Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach.
Kaur K; Kakkar A; Kumar A; Mallick S; Julka PK; Gupta D; Suri A; Suri V; Sharma MC; Sarkar C
Brain Pathol; 2016 May; 26(3):334-43. PubMed ID: 26222673
[TBL] [Abstract][Full Text] [Related]
8. Medulloblastoma: Clinicopathological Correlates of SHH, WNT, and Non-WNT/SHH Molecular Subgroups Analysis and Prognostic Significance: Mono-Institutional Series.
Hasbay B; Kayaselcuk F; Suner HI; Sarialioglu F
Turk Neurosurg; 2022; 32(4):595-602. PubMed ID: 34751426
[TBL] [Abstract][Full Text] [Related]
9. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
[TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
Cambruzzi E
Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
[TBL] [Abstract][Full Text] [Related]
11. Update on the integrated histopathological and genetic classification of medulloblastoma - a practical diagnostic guideline.
Pietsch T; Haberler C
Clin Neuropathol; 2016; 35(6):344-352. PubMed ID: 27781424
[TBL] [Abstract][Full Text] [Related]
12. [Neuropathology of medulloblastomas and other CNS embryonal tumors : Precision diagnostics through the integration of genetic markers].
Pietsch T
Pathologe; 2019 Mar; 40(2):140-147. PubMed ID: 30790012
[TBL] [Abstract][Full Text] [Related]
13. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
14. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
[TBL] [Abstract][Full Text] [Related]
16. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
[TBL] [Abstract][Full Text] [Related]
17. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups.
Eid AM; Heabah NAE
J Egypt Natl Canc Inst; 2021 Feb; 33(1):6. PubMed ID: 33555447
[TBL] [Abstract][Full Text] [Related]
18. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
[TBL] [Abstract][Full Text] [Related]
19. Genetic Markers as Predictors for Response to Treatment and Possible Therapeutic Targets in Medulloblastoma.
Pérez-Pineda PL; Ortiz-Butrón R; Pérez-De Marcos JC; Hernández-Regino LM; Zapata-Tarrés MM; Torres-Espíndola LM
CNS Neurol Disord Drug Targets; 2023; 22(5):634-642. PubMed ID: 35579144
[TBL] [Abstract][Full Text] [Related]
20. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
